Company Overview and News
Noble Energy Inc. (NBL - Free Report) hit a new 52-week high of $35.63 during yesterday’s trading session before closing a tad lower at $35.56. In a year’s time, the stock has delivered a return of 15.7% outperforming its industry’s rally of 10.0%.
Houston, May 16, 2018 (GLOBE NEWSWIRE) -- Noble Energy, Inc. (NYSE: NBL) announced today that Gary W. Willingham, the Company’s Executive Vice President of Operations, will present at the UBS Global Oil and Gas Conference on Thursday, May 24, 2018 at 9:00 a.m. Central Time.
Management focus on friendly investor returns and accelerating natural gas project in Mozambique will support APC’s share in the short and long term.
The U.S. Supreme court announced Monday that it has decided 6-3 to allow states to regulate their own sports gambling, overturning a 1992 law that outlawed sports gambling nationwide except in the state of Nevada where it has been legal for decades.
President Donald Trump on Friday unveiled his plans of lowering drug prices, in keeping with promises he made in the run-up to the Presidential elections. Pharmaceutical companies and the broader industry had been anticipating that Trump would come down heavily on them, as he had long criticized drugmakers of “getting away with murder” by charging way too much for their products.
Merck’s revenues were driven by organic sales growth in its Healthcare and Life Science segments in the fourth quarter. We expect to see the same trend in the upcoming quarterly results.
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process.
Noble Energy, Inc. (NBL - Free Report) finalized an agreement with EPIC Pipeline, LP (“EPIC”) to transport crude oil from Delaware Basin area to Corpus Christi, TX. Per the contract, the company will start transporting 100 thousand barrels of oil per day (MBbl/d) through EPIC pipelines for a period of 10 years starting from the second half of 2019. The 730-mile EPIC crude oil pipeline has a total capacity of 590 MBbl/d and will connect the Permian Basin and the Eagle Ford area to the Port of Corpus Christi.
Apache Corporation (APA - Free Report) recently agreed to participate in the EPIC Crude Oil Pipeline, run by EPIC Midstream Holdings, LP. The strategic alliance also includes Noble Energy, Inc. (NBL - Free Report) . The pipeline will connect southeastern New Mexico to Corpus Christi, TX and transport crude from the Permian Basin and Eagle Ford Shale. The under-construction pipeline will help to clear the infrastructure bottleneck caused by excessive production in the Permian, resulting in lower prices.
Midstream resumed gains this week, with similar gains across MLPs, U.S. and Canadian corps. Oil and the broad stock market rallied as well. No surprise, but $70/bbl seems to be a positive for energy stocks broadly. Midstream-specific sentiment has also benefitted from solid earnings season that included baby steps towards resolution of pending simplifications, de-leveraging, etc. The MLP Index is just one more good week away from being flat for the year (including distributions).
The vessel British Diamond, beneficially owned by BP Plc, is set to arrive at Israel’s Hadera import terminal on May 27 after departing Cheniere Energy Inc.’s Sabine Pass in Louisiana on May 3, ship tracking data compiled by Bloomberg show. Most cargoes to Hadera have come from Trinidad and Tobago, which also ships to the U.S.
Chesapeake Energy stock’s (CHK) implied volatility is ~51.8%. In comparison, Noble Energy (NBL) and Antero Resources (AR) have lower implied volatility, of ~30.5% and ~31.5%, respectively. Meanwhile, the Energy Select Sector SPDR ETF (XLE) has implied volatility of ~19.3%.
HOUSTON -- Noble Energy, Inc. today announced that it has executed, along with the Government of the Republic of Equatorial Guinea and necessary third-parties, a Heads of Agreement establishing the framework for development of natural gas from Alen field located offshore Equatorial Guinea. The agreement outlines the high-level commercial terms for Alen natural gas to be processed through Alba Plant, LLC’s, Liquefied Petroleum Gas plant and EGLNG’s Liquefied Natural Gas (LNG) facility, both located in Punta Europa.
May 10 (Reuters) - EPIC Midstream Holdings LP said on Thursday it formed strategic partnerships with Apache Corp and Noble Energy for its Texas pipeline, which is expected to be in service in the second half of 2019.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
14m - Asif
BUSINESS TrovaGene is a clinical-stage, precision medicine oncology therapeutics company. The company's primary focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its proprietary Precision Cancer Monitoring® (“PCM”) technology in tumor genomics. The company's lead drug candidate, PCM-075, is a Polo-like Kinase 1 (“PLK1”) selective adenosine triphosphate (“ATP”) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and synergy in combination with more than ten different chemotherapeutics and targeted therapies, such as Zytiga® (abiraterone acetate), Beleodaq® (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade® (bortezomib) in Acute Myeloid Leukemia (“AML”), metastatic Castration-Resistant Prostate Cancer (“mCRPC”) and other hematologic and solid tumor cancers. On March 15, 2017, the company announced the licensing of PCM-075, a PLK1 inhibitor...
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
as of ET